

Biophytis participates in the 17th SCWD Congress and hosts an *Obesity Investor Call*

Paris, France and Cambridge (Massachusetts, USA), [December 2, 2024] – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS; Nasdaq CM: BPTS), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, announces its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8, 2024, in Washington, D.C.

As part of the congress, Biophytis will host an **Obesity Investor Call** on the topic: "**GLP-1 RA weight loss therapy-induced muscle loss: A medical need to explore?**". The panel of experts will feature key opinion leaders in clinical and medical research:

- **Professor Roger Fielding**, Professor of Nutrition and Medicine, Tufts University
- **Professor Marc André Cornier**, Endocrinologist, Medical University of South Carolina
- **Professor William Evans**, Associate Professor of Human Nutrition, University of California, Berkeley

This session will provide participants with a deeper understanding of the clinical implications and potential therapeutic solutions to counter the side effects of GLP-1 RA obesity treatments. **Stanislas Veillet**, CEO and Founder of Biophytis, will present the company's strategic positioning in this field, and the session will be moderated by **Rob Van Maanen**, Chief Medical Officer of Biophytis.

The event will take place on **Friday, December 6, at 12:45 PM ET (6:45 PM CET)**. Analysts and investors can register and join the event remotely via this link: https://uptownevents-co-uk.zoom.us/webinar/register/WN_HfHAmCayQ76gcpFw9MGT6Q

* * * *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contact Biophytis

[Investor relations](#)

Investors@biophytis.com

Media contacts

[Antoine Denry: antoine.denry@taddeo.fr](mailto:antoine.denry@taddeo.fr) – +33 6 18 07 83 27

[Inès de Mandiargues: ines.demandiargues@taddeo.fr](mailto:ines.demandiargues@taddeo.fr) - +33 6 16 16 51 78